Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain
IntroductionDespite the high efficacy of the anti-coronavirus disease 2019 (COVID-19) BNT162b2 vaccine (Comirnaty®, Pfizer-BioNTech), variability in the antibody titers following vaccination has been described. However, little is known about the risk factors that are associated with a poorer antibod...
Saved in:
| Main Authors: | Luis Sarabia de Ardanaz, Esther Serrano-Conde, Ana Fuentes, Alba Leyva, Federico García, Pilar Requena |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1590939/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01) -
A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting
by: Aini Syahida Mat Yassim, et al.
Published: (2025-07-01) -
Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01) -
Löfgren’s Syndrome Following BNT162b2 mRNA COVID-19 Vaccination and Subsequent Plaque-type Cutaneous Sarcoidosis after its Resolution
by: Masahiro Oka, et al.
Published: (2025-06-01) -
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)